Human, an Australian health tech company, has raised $46 million to build a system that tracks which treatments work best for real patients. The funding is led by Airtree Ventures, with New York growth firm Left Lane Capital also backing it, according to Airtree Ventures.

Here's what the company does: it collects medical information from doctors, researchers, and patients to figure out which treatments produce the best outcomes. Instead of waiting years for formal drug trials to be published, Human tries to surface what is actually working in everyday practice — adjusted for each patient's specific situation. This is different from most health software companies, which typically just manage medical records or process insurance claims.

The investor mix matters. Airtree is one of Australia's most active growth-stage investors, with a strong record backing enterprise software and deep technology companies. Left Lane Capital focuses on health businesses that build durable relationships with customers and grow stronger as they add more data — the kind where the platform gets more valuable the more it is used. Both firms betting on the same company is a signal of confidence in both Australia as a market and the company's potential to expand internationally.

At $46 million, this is a substantial raise for an Australian tech company — larger than the typical Series B, which usually lands in the $15–30 million range. The size reflects how expensive it is to build and test a system that doctors and hospitals can trust with clinical decisions.

After the peak of health tech hype in 2021 and 2022, investors have become pickier. Money is still flowing to healthcare startups, but mainly those with defensible data and a clear path through regulatory requirements. A raise this size in 2026, with established investors on board, indicates Human has cleared early diligence hurdles.

The tougher challenge lies ahead. Companies using observational patient data face a well-known hurdle: moving from "here's what seems to work" to "here's evidence doctors should actually trust." Hospitals need rigorous proof before they switch to a new system. Whether Human has solved this problem is not yet clear from the funding news.

What the money does guarantee is time to pursue an answer. Forty-six million dollars provides runway for data partnerships, regulatory work, and formal studies to prove the platform is reliable. How Human spends that capital — whether it deepens its presence in Australia first or moves internationally — will determine its next chapter.